![Giuseppina Caligiuri](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Positionen von Giuseppina Caligiuri
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Tridek-One Therapeutics SAS
![]() Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Direktor/Vorstandsmitglied | 01.06.2018 | - |
Gründer | 01.06.2018 | - |
Karriereverlauf von Giuseppina Caligiuri
Statistik
International
Frankreich | 2 |
Operativ
Director/Board Member | 1 |
Founder | 1 |
Sektoral
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Tridek-One Therapeutics SAS
![]() Tridek-One Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Tridek-One Therapeutics SAS is a French private biotechnology company founded in 2018. The company is based in Paris, France. Tridek-One's scientific founders at INSERM conducted groundbreaking research on the role of CD31 in the modulation of the immune response, which forms the basis of the company's work. The company was founded in 2019 by Giuseppina Caligiuri, Antonino Nicoletti, and the CEO is Laurence de Schoulepnikoff. | Commercial Services |
- Börse
- Insiders
- Giuseppina Caligiuri
- Erfahrung